Fixed Venetoclax Dosing May Not Be Feasible for All Patients

Fixed Venetoclax Dosing May Not Be Feasible for All Patients With CLL

The retrospective cohort study evaluated data from 116 patients who received venetoclax as part of their first-line treatment and 145 patients in the relapsed/refractory setting..

Related Keywords

United States , , Journal Of The National Comprehensive Cancer Network , Astrazeneca Pharmaceuticals , National Comprehensive Cancer , Metrics Plus , Southern United ,

© 2025 Vimarsana